Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | DAO | P14920 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 4/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | APEX1 | P27695 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2949425 | 0.98 | GLA (0.53) | GLACYP1A2SMN1; SMN2MAPK1DAO | |
| SCHEMBL19464841 | 0.89 | SMN1; SMN2 (0.58) | GLACYP1A2SMN1; SMN2MAPK1DAO | |
| SCHEMBL13515770 | 0.85 | GLA (0.47) | GLACYP1A2SMN1; SMN2MAPK1LMNA | |
| SCHEMBL13993887 | 0.84 | PAOX (0.47) | SMN1; SMN2DAOMAOBBCHEACHE | |
| SCHEMBL24911981 | 0.83 | GLA (0.46) | GLACYP1A2SMN1; SMN2MAPK1LMNA | |
| SCHEMBL7027263 | 0.82 | GLA (0.67) | GLACYP1A2SMN1; SMN2MAPK1LMNA | |
| SCHEMBL3973280 | 0.82 | GLA (0.67) | GLACYP1A2SMN1; SMN2MAPK1LMNA | |
| SCHEMBL1069692 | 0.82 | — | — | |
| SCHEMBL6536452 | 0.82 | GLA (0.67) | GLACYP1A2SMN1; SMN2MAPK1LMNA | |
| SCHEMBL29972868 | 0.82 | L3MBTL1 (0.57) | SMN1; SMN2DAOMAOBBCHEACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023223055-A1 | ANTI-VIRAL COMPOUNDS | Infex Therapeutics Limited (GB) | 2023-11-23 | — | — | WO | disclosed |
| US-20230149401-A1 | FURIN INHIBITORS FOR TREATING CORONAVIRUS INFECTIONS | BP ASSET V, INC. (US) | 2023-05-18 | — | — | US | disclosed |
| US-20230011571-A1 | SMALL MOLECULE FURIN INHIBITORS FOR TREATING INFECTIOUS DISEASES | BP ASSET V, INC. (US) | 2023-01-12 | — | — | US | disclosed |
| US-11530199-B2 | Analogs for the treatment of disease | INSILICO MEDICINE IP LIMITED (HK) | 2022-12-20 | — | — | US | disclosed |
| US-11530197-B2 | Analogs for the treatment of disease | INSILICO MEDICINE IP LIMITED (HK) | 2022-12-20 | — | — | US | disclosed |
| WO-2022189810-A1 | ANTI-VIRAL COMPOUNDS | Infex Therapeutics Limited (GB) | 2022-09-15 | — | — | WO | disclosed |
| US-20220127613-A1 | Functionally-Modified Oligonucleotides And Subunits Thereof | SAREPTA THERAPEUTICS INC (US) | 2022-04-28 | — | — | US | disclosed |
| US-11161856-B2 | Spirocycle compounds and methods of making and using same | H. LUNDBECK A/S (DK) | 2021-11-02 | — | — | US | disclosed |
| US-10300075-B2 | Compounds that inhibit MCL-1 protein | AMGEN INC. (US) | 2019-05-28 | — | — | US | disclosed |
| US-10183944-B2 | Pyrimido-pyridazinone compounds and methods of use thereof | ASANA BIOSCIENCES, LLC (US) | 2019-01-22 | — | — | US | disclosed |
| US-9790499-B2 | Functionally-modified oligonucleotides and subunits thereof | SAREPTA THERAPEUTICS, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-20170157126-A1 | USES OF PYRIMIDO-PYRIDAZINONES TO TREAT CANCER | ASANA BIOSCIENCES, LLC (US) | 2017-06-08 | — | — | US | disclosed |
| US-20170145020-A1 | 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS,COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-05-25 | — | — | US | disclosed |
| US-20090209511-A1 | Benzofuran Derivatives | KAWAGUCHI TAKAYUKI | 2009-08-20 | — | — | US | disclosed |
| US-20090209511-A1 | Benzofuran Derivatives | KAWAGUCHI TAKAYUKI | 2009-08-20 | — | — | US | disclosed |
| CN-100439351-C | Benzofuran derivative | TANABE SEIYAKU CO (JP) | 2008-12-03 | — | — | CN | disclosed |
| CN-1656086-A | Benzofuran derivative | TANABE SEIYAKU CO (JP) | 2005-08-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10183944-B2 | Pyrimido-pyridazinone compounds and methods of use thereof | THPO, TYMP, TYMS | GLA 3847/4885CYP1A2 258/4885SMN1; SMN2 1227/4885 |
| US-11530199-B2 | Analogs for the treatment of disease | MAP4K4, MAP4K5, MAP4K2 | GLA 1085/4885CYP1A2 2718/4885SMN1; SMN2 651/4885 |
| US-11161856-B2 | Spirocycle compounds and methods of making and using same | OPRL1, MGLL, VKORC1L1 | GLA 1168/4885CYP1A2 1248/4885SMN1; SMN2 1308/4885 |
| US-20230011571-A1 | SMALL MOLECULE FURIN INHIBITORS FOR TREATING INFECTIOUS DISEASES | FURIN, LGMN, PLAU | GLA 228/4885CYP1A2 4762/4885SMN1; SMN2 1227/4885 |
| US-20170157126-A1 | USES OF PYRIMIDO-PYRIDAZINONES TO TREAT CANCER | MKI67, DPYD, TYMP | GLA 2900/4885CYP1A2 1702/4885SMN1; SMN2 1603/4885 |
| US-20230149401-A1 | FURIN INHIBITORS FOR TREATING CORONAVIRUS INFECTIONS | FURIN, ACE, ACE2 | GLA 577/4885CYP1A2 3332/4885SMN1; SMN2 4024/4885 |
| US-11530197-B2 | Analogs for the treatment of disease | MAP4K4, MAP4K5, MAP4K2 | GLA 1085/4885CYP1A2 2718/4885SMN1; SMN2 651/4885 |
| US-10300075-B2 | Compounds that inhibit MCL-1 protein | MCL1, BCL9, BCL2L1 | GLA 3242/4885CYP1A2 3986/4885SMN1; SMN2 1842/4885 |
| US-20090209511-A1 | Benzofuran Derivatives | F12, F2, F3 | GLA 1656/4885CYP1A2 87/4885SMN1; SMN2 3067/4885 |
| US-20220127613-A1 | Functionally-Modified Oligonucleotides And Subunits Thereof | RTCB, NSUN3, NSUN2 | GLA 3321/4885CYP1A2 4739/4885SMN1; SMN2 203/4885 |
| US-20170145020-A1 | 5-CHLORO-2-DIFLUOROMETHOXYPHENYL PYRAZOLOPYRIMIDINE COMPOUNDS,COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, FLT3 | GLA 3819/4885CYP1A2 172/4885SMN1; SMN2 3594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.